PaxMedica, Financial Statements From 2010 to 2026
| PXMD Stock | USD 0.0001 0.00 0.00% |
Check PaxMedica, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PaxMedica,'s main balance sheet or income statement drivers, such as , as well as many indicators such as . PaxMedica, financial statements analysis is a perfect complement when working with PaxMedica, Valuation or Volatility modules.
PaxMedica, |
PaxMedica Common Stock Company Return On Equity Analysis
PaxMedica,'s Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current PaxMedica, Return On Equity | -10.47 |
Most of PaxMedica,'s fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PaxMedica Common Stock is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, PaxMedica Common Stock has a Return On Equity of -10.4696. This is 56.32% lower than that of the Biotechnology sector and 71.28% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
PaxMedica Common Stock Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PaxMedica,'s current stock value. Our valuation model uses many indicators to compare PaxMedica, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PaxMedica, competition to find correlations between indicators driving PaxMedica,'s intrinsic value. More Info.PaxMedica Common Stock is regarded second in return on equity category among its peers. It is regarded third in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PaxMedica,'s earnings, one of the primary drivers of an investment's value.About PaxMedica, Financial Statements
PaxMedica, stakeholders use historical fundamental indicators, such as PaxMedica,'s revenue or net income, to determine how well the company is positioned to perform in the future. Although PaxMedica, investors may analyze each financial statement separately, they are all interrelated. For example, changes in PaxMedica,'s assets and liabilities are reflected in the revenues and expenses on PaxMedica,'s income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PaxMedica Common Stock. Please read more on our technical analysis and fundamental analysis pages.
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC. Paxmedica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Other Information on Investing in PaxMedica, Pink Sheet
PaxMedica, financial ratios help investors to determine whether PaxMedica, Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PaxMedica, with respect to the benefits of owning PaxMedica, security.